Released Feb 25, 2022, before the open
10-K filed Feb 25, 2022, 56 days after period end · 0001564590-22-006929
Q4 2021 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$125.06M$125.06M derived+6.3% vs Q4 2020+11.2% vs Q3 2021
Net Income-$32.81M-$32.81M derivedN/M vs Q4 2020N/M vs Q3 2021
EPS, diluted—Not derived. Share counts vary by quarter.
Gross Profitderived$91,810,000+3.7%
Operating Incomederived-$9,353,000N/M
Operating Cash Flowderived$11,779,000−47.2%
Free Cash Flowderived$5,554,000−69.9%
Margins · derived
Gross margin73.4%−1.9 pt vs Q4 2020
Operating margin-7.5%−10.6 pt vs Q4 2020
Net margin-26.2%−18.3 pt vs Q4 2020
What the release said
The release
Same quarter
| Metric | Q4 2021dderived from reported figures | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018 |
|---|---|---|---|---|
| Revenue | $125.06M | $117.62M | $121.49M | $121.08M |
| Net Income | -$32.81M | -$9.38M | $11.69M | $8.87M |
| EPS Diluted | — | — | $0.60 | $0.46 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Orthofix Medical Inc. · CIK 884624 · Engraved from SEC EDGAR